598A
AASLD ABSTRACTS
913
FAMILIAL LIVER ADENOMATOSIS ASSOCIATED WITH HEPATOCYTE NUCLEAR FACTOR 1 ALPHA INACTIVATION. Yannick Bacq, H6pital Trousseau, Tours, France;
mmanuel Jacquemin, H6pital de Bic~tre, Le Kremlin Bic~tre, France; Charles Balabaud, H6pita! de Bordeaux, Bordeaux, France; mmanuelle Jeannot, INS~ RM U434, ~ PH-Fondah'on Jean Dausset, Paris, France; B~atfice Scotto, H6pital Trousseau, Tours, France; Sophie Branchereau, H6pital de Bic~tre, Le Kremlin Bic~tre, France; Christophe Laurent, H6pital de Bordeaux, Bordeaux, France; Pascal Bourlier, H6pital Trousseau, Tours, France; Daniel Pariente, H6pital de Bic~tre, Le Kremlin Bic~tre, France; Anne de Muret, H6pital Trousseau, Tours, France; Monique Fabre, H6pital de Bic~tre, Le Kremlin Bic~tre, France; Paulette Bioulac-Sage, H6pital de Bordeaux, Bordeaux, France; Jessica Zucman-Rossi, INS~ RM U434, ~ PHFondah'on Jean Dausset, Paris, France Background and Aims: Germline mutations in the hepatocyte nuclear factor I alpha (TCF1/HNF1) are associated with maturityonset diabetes of the young type 3 (MODY3) and somatic biallelic inactivations of the gene are found in hepatocellular adenomas and liver adenomatosis (Nature genetics, 2002;32:312-315). This study investigated cosegregation of TCF1/HNF1 germline mutations with diabetes and liver adenomatosis in two families. Methods: Two patients suffering from liver adenomatosis were screened for TCF1/HNF1 germline and somatic mutations. Subsequenfiy, we screened 9 relatives in the two i n d e p e n d e n t families for diabetes, hepatocellular adenomas and TCF1/HNF1 germline mutations. Results: In family A, a father and his son presented with an intra-peritoneal hemorrhagic rupture of a liver adenomatosis without diabetes. A heterozygous R229X germline mutation was identified in TCF1/HNF1 in the father and his son, and also in his second 27-year-old son without hepatocellular adenomas. In family B, a diagnosis of liver adenomatosis was made fortuitously in a 14-year-old girl. A heterozygous G55fsX57 germline mutation in TCF1/HNF1 was identified in this patient, in her diabetic father and her two sisters. Systematic exploration with ultrasonography and magnetic resonance imaging revealed liver adenomatosis in the two sisters. Somatic inactivation of the second TCF1/HNF1 allele was found in liver tumors in both families. Conclusion: This study describes familial liver adenomatosis and shows their association with germline TCF1/HNF1 mutations in adults and children. It also highlights the importance of a screening for hepatocellular adenomas, diabetes and TCF1/HNF1 germline mutations in relatives of patients with liver adenomatosis. Finally, prevalence of liver adenomatosis remains to be evaluated in MODY3 subjects. Disclosures: Yannick Bacq - No relationships to disclose Charles Balabaud - No relationships to disclose Paulette Bioulac-Sage - No relationships to disclose Pascal Bourlier - No relationships to disclose Sophie Branchereau - No relationships to disclose Anne de Muret - No relationships to disclose Monique Fabre - No relationships to disclose Emmanuel Jacquemin - No relationships to disclose Emmanueile Jeannot - No relationships to disclose Christophe Laurent - No relationships to disclose Daniel Pariente - No relationships to disclose B6atrice Scotto - No relationships to disclose Jessica Zucman-Rossi - No relationships to disclose
914
HEPARANASE EXPRESSION DURING NORMAL LIVER DEVELOPMENT AND LIVER REGENERATION FOLLOWING PARTIAL HEPATECTOMY. Om't Goldshmidt, Rita Yeikilis, Melia
Paizi, Israel Vlodavsky, Gadi Spira, Technion - Israel Institute of Technology, Haifa, Israel Heparan sulfate proteoglycans (HSPG) are a major component of the extracellular matrix (ECM), playing an essential role in maintaining the integrity and functional state of tissues and organs. Cleavage of HSPGs may thus influence normal and pathological processes including architectural changes, cell migration and re-
HEPATOLOGY, October 2003
sponse to heparin-binding growth factors sequestered by the ECM. Heparanase is a mammalian endoglycosidase capable of a specific cleavage of heparan sulfate chains (HS). Our study points for a possible involvement of heparanase during normal liver development and liver regeneration following partial hepatectomy. Utilizing in situ hybridization, immunohistochemistry and Western blotting we have shown that heparanase mRNA and protein are notably expressed in the embryonic normal liver (18 and 22 weeks) while absence from the mature healthy liver (human, or rat). In a 39 week h u m a n embryo liver, only Kupffer cells were stained as compared to strong cellular staining of hepatocytes in the liver of the 18 and 22 weeks embryos. In the regenerating rat liver, a peak of heparanase expression appears as early as12 hours post surgery. A second prominent peak was evident at day seven (168 hours). Heparanase cellular distribution alternates during the regenerative phase from homogenous cytoplasmic staining (till 96 hours) to a polar granular pattern adjacent to the cell membrane, at 168 hours post hepatectomy. In order to assess other ECM degrading enzymes previously demonstrated to be involved in liver regeneration a gelatin zymography of MMP-2 and MMP-9 was used. Based on our results we propose, for the first time, that heparanase may play an important role in liver development and regeneration. Disclosures: Orit Goldshmidt - No relationships to disclose Melia Paizi - No relationships to disclose Gadi Spira - No relationships to disclose Israel Vlodavsky - No relationships to disclose Rita Yeikilis - No relationships to disclose
915 EXPRESSION
O F T N F - R E L A T E D A P O P T O S I S INDUCING LIGAND IN HUMAN HEPATOCELLULAR CARCINOMA.
Katsuya Shiraki, Takenari Yamanaka, Hiroshi Okano, Tomoyuki Kawakita, Yukiko Saitou, Yumi Yamaguchi, Kazushi Sugimoto, Kazumoto Murata, Takeshi Nakano, 1st Medicine, Mie University, Tsu, Japan Backgroud:TNF-related apoptosis-inducing ligand (TRAIL), as well as Fas ligand, plays a pivotal role in lymphocyte cytotoxicity and the maintenance of immunological homeostasis in various tissues, but its physiological role in immune evasion of cancer ceils remains unknown. We have previous shown strong resistance to TRAIL-induced cytotoxicity in h u m a n hepatocellular carcinomas (HCCs). However, the TRAIL expression and its function in HCC was not well elucidated. Therefore, the current study investigates the expression of TRAIL in HCCs. Methods: mRNA and protein expression of TRAIL were examined by RT-PCR, western blotting, immunohistochemical staining and flow cytometry in HCC cell lines and HCC tissues. TRAIL expression was analyzed using HCC ceils treated with doxorubicin, other chemotherapeutic drugs and various cytokines. Function of TRAIL was analyzed using co-culture experiments with Jurkat ceils which is sensitive to TRAIL. Results:We found that three HCC ceils, HepG2, Hep3B and Huh7 ceils, constitutively express TRAIL mRNA and protein, as detected by RT-PCR and Western blotting. Four of 10 h u m a n HCC tissues also demonstrated positive staining for TRAIL, whereas non-tumor tissues showed little detectable staining. TRAIL located in both cytoplasm and membrane. TRAIL expression on tumor ceils was also detected by flow cytometry and furthermore was dramatically induced after the addition of doxorubicin, a chemotherapeutic agent, or NF-KB activating cytokine stimulation with TNF-cY, IL-1/3 or IL-18 in all HCC cell lines examined. This upregulation of TRAIL was also confirmed by Western blotting. In addition, this expression was induced principally via the NF-KB activation pathway, since IKB transfection significantly reduced TRAIL expression. In addition, the expressed TRAIL was functional. The TRAIL on HCC ceils induced apoptosis in Jurkat ceils that are sensitive to TRAIL-mediated apoptosis, and this process was specifically inhibited by recombinant TRAIL-receptors:Fc which binds to TRAIL. This inhibitory effect was stronger than that using anti-FasL antibody. Conclusions; TRAIL expressed on the surface of HCC ceils by cytokines